A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)
Phase of Trial: Phase 0
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Entinostat (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 31 Jan 2018 Status changed from not yet recruiting to recruiting.
- 16 Jan 2018 Planned initiation date changed from 15 Dec 2017 to 22 Jan 2018.